Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Big Are Gilead's Latest COVID Wins?

TheMotleyFool

0 0

The U.S. Food and Drug Administration (FDA) recently expanded the label for Gilead Sciences' (NASDAQ: GILD) COVID-19 therapy Veklury (remdesivir) to be used in treating non-hospitalized adults. In addition, the agency expanded the Emergency Use Authorization (EUA) for the drug to include children below age 12. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli discuss how big these latest COVID-19 wins are for Gilead.

Source Fool.com

Like: 0

GILD

Share